Sitagliptin: Clinical Trials

96 trials of Sitagliptin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

78 completed, 9 terminated, 4 withdrawn, 3 unknown. 96 Phase 3, 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 396Completed 78, Terminated 9, Withdrawn 4, Unknown 3, Not yet recruiting 1, Recruiting 1
Phase 27Completed 6, Not yet recruiting 1

Follow Sitagliptin: new trials by email Literature Review of Sitagliptin trials Research Report on Sitagliptin

Trials (filtered) newest first · largest first

All 96 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes
Tirzepatide, Pioglitazone, Sitagliptin - Type 2 Diabetes (Adult Onset)
Phase 3RecruitingThe University of Texas Health Science Center at San Antonio2562024-11-072026-03-10
Effects of Sitagliptin in Relatives of T1D Patients
Sitagliptin, Professional CGM - Type 1 Diabetes
Phase 2 / Phase 3Not yet recruitingUniversity of Milan702023-07-012023-05-10
The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients
Sitagliptin - Covid19, Diabetes Mellitus, Type 2
Phase 3UnknownUniversity of Milan1702021-12-292021-09-28
Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study
Metformin Extended Release Oral Tablet, Sitagliptin - Type 1 Diabetes, Monogenic Diabetes
Phase 2 / Phase 3CompletedJoslin Diabetes Center32021-08-262025-02-24
Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)
Canagliflozin, Sitagliptin - Diabetes Mellitus, Type 2, Cognitive Functions Confusion
Phase 3CompletedThird Military Medical University1002021-07-012024-05-30
A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes
Oral semaglutide, Sitagliptin, Placebo (oral semaglutide) - Diabetes Mellitus, Type 2
Phase 3CompletedNovo Nordisk A/S14412019-07-292024-10-01
Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
Bexagliflozin, Sitagliptin, Placebo for sitagliptin - Type 2 Diabetes Mellitus
Phase 3CompletedTheracos3862017-10-122021-06-22
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)
Semaglutide 0.5 mg, Semaglutide 1.0 mg, Sitagliptin placebo - Diabetes, Diabetes Mellitus, Type 2
Phase 3CompletedNovo Nordisk A/S8682017-08-282021-03-02
Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin
Ipragliflozin, Sitagliptin - Type 2 Diabetes Mellitus
Phase 3CompletedSeoul National University Bundang Hospital1702017-04-252022-10-04
Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes
triple combination therapy, Stepwise add-on therapy - Diabetes Mellitus, Type II
Phase 3UnknownKorea University Anam Hospital1042016-12-012016-10-27
Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.
semaglutide, sitagliptin - Diabetes, Diabetes Mellitus, Type 2
Phase 3CompletedNovo Nordisk A/S5042016-09-202022-07-20
A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)
Sitagliptin, Placebo, Metformin IR - Type 2 Diabetes Mellitus
Phase 3CompletedMerck Sharp & Dohme LLC4582016-06-162019-02-28
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
Sitagliptin, Placebo to sitagliptin, Metformin - Type 2 Diabetes Mellitus
Phase 3CompletedMerck Sharp & Dohme LLC7462016-05-092019-02-25
Accelerated Wound Healing in Diabetic Ulcers by Sitagliptin
Sitagliptin, Placebo - Diabetic Foot
Phase 3WithdrawnWolfgang-Michael Franz2016-03-012016-09-15
Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes
semaglutide, sitagliptin, placebo - Diabetes, Diabetes Mellitus, Type 2
Phase 3CompletedNovo Nordisk A/S18642016-02-152022-07-20
Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)
Ipragliflozin, Placebo, Sitagliptin - Type 2 Diabetes Mellitus
Phase 3CompletedMerck Sharp & Dohme LLC1432015-11-092018-09-04
Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)
Sitagliptin, Placebo, Ipragliflozin - Type 2 Diabetes Mellitus
Phase 3CompletedMerck Sharp & Dohme LLC1412015-11-052018-08-31
Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)
Ipragliflozin, Sitagliptin - Type 2 Diabetes Mellitus
Phase 3CompletedMerck Sharp & Dohme LLC772015-10-262018-09-04
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
Sitagliptin, Dapagliflozin, Metformin - Type 2 Diabetes Mellitus
Phase 3CompletedMerck Sharp & Dohme LLC6142015-10-202018-11-20
Sitagliptin Therapy and Kinetics of Inflammatory Markers
Sitagliptin, Placebo - Type 2 Diabetes Mellitus
Phase 3CompletedLaval University202015-08-012020-05-13

Showing 20 of 96. Sign in to see all of them.

Conditions studied

Diabetes Mellitus, Type 2 (84)  ·  Diabetes Mellitus (24)  ·  Diabetes Mellitus, Type 1 (3)  ·  Inflammation (3)  ·  Renal Insufficiency (3)  ·  Cardiovascular Diseases (2)  ·  Hyperlipidemias (2)  ·  Renal Insufficiency, Chronic (2)  ·  Atherosclerosis (1)  ·  Body Weight (1)  ·  COVID-19 (1)  ·  Confusion (1)  ·  Cystic Fibrosis (1)  ·  Diabetic Foot (1)  ·  Endocrine System Diseases (1)

Sponsors

Merck Sharp & Dohme LLC (31)  ·  Novo Nordisk A/S (9)  ·  AstraZeneca (6)  ·  Janssen Research & Development, LLC (3)  ·  Laval University (3)  ·  Boehringer Ingelheim (2)  ·  GlaxoSmithKline (2)  ·  Intarcia Therapeutics (2)  ·  Michael A. Nauck (2)  ·  Novartis (2)  ·  Phenomix (2)  ·  Sanofi (2)  ·  Takeda (2)  ·  University of Milan (2)  ·  Washington University School of Medicine (2)

Countries

United States (35)  ·  Mexico (16)  ·  South Korea (16)  ·  Canada (15)  ·  India (15)  ·  Germany (14)  ·  South Africa (13)  ·  Poland (12)  ·  Argentina (11)  ·  Romania (11)  ·  Spain (11)  ·  Russia (10)  ·  Hungary (9)  ·  United Kingdom (9)  ·  Brazil (8)

Top investigators

Kevin E Yarasheski, PhD (2)  ·  Michael A. Nauck, Prof. Dr. (2)  ·  Patrick Couture, MD, PhD (2)  ·  Arlene A Stecenko, MD (1)  ·  Astra Zeneca (1)

Results publications

PMID 32998732, PMID 24517339, PMID 24742013, PMID 24786834, PMID 24918789, PMID 25329038, PMID 25813214, PMID 26121561, PMID 26373629, PMID 26580237, PMID 27600862, PMID 27977934, PMID 28197834, PMID 28241822, PMID 28327140, PMID 31797522, PMID 31903692, PMID 32306296, PMID 32324065, PMID 32324082, PMID 32372382, PMID 32648108, PMID 38770818, PMID 23522121, PMID 23748506, PMID 23748507, PMID 26579834, PMID 30880443, PMID 32267058, PMID 32700393, PMID 33660198, PMID 34033212, PMID 35373893, PMID 37178435, PMID 39963952, PMID 10752702, PMID 16033281, PMID 18539916, PMID 18539917, PMID 18784090, PMID 19073764, PMID 19114612, PMID 19336687, PMID 19689275, PMID 20417856, PMID 20580422, PMID 21199268, PMID 21205123, PMID 21309842, PMID 21355967

NIH funding

2015 (5), 2008 (4), 2014 (3), 2009 (1), 2018 (1), R01DK097554 (1), U01DK098246 (1)